Atrial Fibrillation, Sleep Apnea
Conditions
Keywords
sleep apnea, atrial fibrillation
Brief summary
The investigators will screen consecutive patients presenting to the atrial fibrillation clinic for sleep apnea using a FDA-approved home sleep testing device, WatchPAT to determine prevalence of sleep apnea in a clinic-based sample.
Detailed description
The investigators will determine the prevalence of sleep apnea among consecutive patients with atrial fibrillation (AF) regardless of symptoms and determine the predictive value of screening tools for sleep apnea in this population. The primary outcome will be the prevalence of sleep apnea among all-comers with AF. Three secondary outcomes will be evaluated in the study. Investigators will determine the efficiency and time-to-diagnosis of sleep apnea using a FDA approved home sleep testing device (i.e. WatchPAT). These analyses will be compared to published studies performed using a traditional home sleep study test (which historically takes approximately 8-10 weeks). There will be no collection of data from a non-intervention group in our study. Second, investigtaors will calculate the predictive value of traditional clinical screening tools in an AF population using the STOP-BANG questionnaire and Epworth Sleepiness Scale. Third, investigators will identify potential risk factors for AF in patients with sleep apnea using a logistic regression model.
Interventions
DEVICEWatchPAT
FDA-approved portable home sleep testing device worn on the wrist.
Sponsors
Itamar-Medical, Israel
Brigham and Women's Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Diagnosis of AF confirmed on any electrocardiographic recording * Age greater than or equal to 18 * Ability to read and understand consent form, complete questionnaires, and provide informed consent
Exclusion criteria
* Prior diagnosis of sleep disordered breathing or negative testing within the past 2 years without significant change in weight or clinical symptoms of sleep apnea * History of Raynaud
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of sleep apnea | 2 year study | Prevalence of sleep apnea among patients with atrial fibrillation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Risk factors | 2 years | We will identify potential risk factors for AF in patients with sleep apnea using a logistic regression model |
| Time to diagnosis | 2 years | We will determine the efficiency and time-to-diagnosis of sleep apnea using a FDA approved home sleep testing device (i.e. WatchPAT) |
| Predictive value of typical screening tools | 2 years | We calculate the predictive value of traditional clinical screening tools in an AF population using the STOP-BANG questionnaire and Epworth Sleepiness Scale |
| Quality of life | 2 years | We will compare quality of life using the MAFSI in atrial fibrillation patients with and without sleep apnea. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Autonomic index | 2 years | Compare autonomic index in patients with AF who have sleep apnea versus those without sleep apnea |
| Insomnia Severity Index | 2 years | Assess prevalence of insomnia among consecutive patients with atrial fibrillation |
Countries
United States
Contacts
Primary ContactSogol Javaheri, MD
Backup ContactElliott Antman, MD
Outcome results
None listed